Search
for
Sort by
Research 481–510 of 1000+
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Combination Treatment with Methotrexate for Severe Alopecia Areata
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- British Association of Dermatologists living guideline for managing people with alopecia areata 2024
- Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
- The correlation between corona virus disease 2019 and alopecia areata: a literature review
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
- Detection of Serum Levels of Interleukins-17, 21, 6 and Tumor Necrosis Factor-α in Patients with Patchy Alopecia Areata and Their Association with Disease Severity
- Prescribing patterns amongst UK dermatologists for the treatment of alopecia areata, female pattern hair loss, and frontal fibrosing alopecia
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Systemic corticosteroids in vitiligo: Evidence-based insights and practical considerations
- Retrospective Analysis of Systemic Corticosteroids for Alopecia Areata in Pediatric Patients
- ASSOCIATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND CHRONIC GRANULOMATOUS DISEASE IN ADULTS: REPORT OF 2 CASES
- CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata
- Efficacy of systemic minoxidil and tofacitinib combination in treatment‐resistant alopecia universalis
- MIXED CONNECTIVE TISSUE DISEASE EVOLVING FROM THE SEQUENTIAL OVERLAP OF SYSTEMIC LUPUS ERYTHEMATOSUS, SJÖGREN’S SYNDROME, RHEUMATOID ARTHRITIS AND DERMATOMYOSITIS: A FOLLOW-UP
- Advances in the Molecular Pathogenesis and Targeted Therapy of Psoriasis
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- What’s new in the treatment of hair loss?
- Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
- Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
- Advances in dermatology research: A comprehensive literature review
- Modern Management Approaches for Alopecia Areata
- New Treatments for Hair Loss